Jiangsu Yahong Meditech Co., Ltd. (“Asieris”; Stock Code: 688176.SH) completed its IPO and listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange (SSE STAR Market) on January 7, 2022. The company offered 110 million shares at RMB 22.98 per share, raising approximately RMB 2.528 billion.

Asieris is a global innovative drug producer in the fields of urogenital system tumors and other major diseases. With the mission of "improving human health and making life more dignified", the company aims to be a world leading pharmaceutical enterprise engaged in the R&D, production and commercialization of therapeutic drugs. It provides patients with integrated solutions for diagnosis and treatment.

As the legal adviser to the sponsor, while offering legal solutions and opinions, Jingtian & Gongcheng's legal team provided comprehensive legal services, including but not limited to making IPO-related materials such as application documents, and other documents needed by the company and sponsor, assisting in application and answering inquiries from the regulator, thus assisting the company in successful listing.